Skip to main content
SpringerLink
Log in

Response-Related Predictors of Survival in CML

  • Chapter
  • First Online:
Chronic Myeloid Leukemia

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1410 Accesses

Abstract

The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be linked to long-term survival outcomes as well. Therefore, the quantification of molecular or cytogenetic response as early as 3 months on treatment allows a prognostic stratification of a patient’s individual risk. With competing TKI regimens available, a timely switch of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI, and for second-line TKI treatment as well.

Parts of this chapter have formerly been published within the journal Annals of Hematology in Volume 94, Issue 2, supplement, April 2015, “Chronic Myeloid Leukemia,” doi:10.1007/s00277-015-2327-x.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alvarado Y, Kantarjian H, O’Brien S, Faderl S, Borthakur G, Burger J et al (2009) Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709–3718, Epub 2009/06/12. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1(11):710–719, Epub 1983/11/01. eng

    CAS  PubMed  Google Scholar 

  • Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051, Epub 2009/11/04. eng

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884, Epub 2013/06/28. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S et al (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17(12):2401–2409, Epub 2003/10/03. eng

    Article  CAS  PubMed  Google Scholar 

  • Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC et al (2012) Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 30(35):4323–4329, Epub 2012/10/31. eng

    Article  CAS  PubMed  Google Scholar 

  • Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121(19):3818–3824, Epub 2013/03/22. eng

    Article  CAS  PubMed  Google Scholar 

  • Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al (2014) Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124:511–518. 20140725 DCOM- 20141118(1528-0020 (Electronic)). eng

    Google Scholar 

  • Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D et al (2014) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 8, Epub 2014/09/10. Eng

    Google Scholar 

  • Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al (2009) International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib. ASH Annu Meet Abst 114(22):1126

    Google Scholar 

  • Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118(26):6760–6768, Epub 2011/11/01. eng

    Article  CAS  PubMed  Google Scholar 

  • Hanfstein B, Muller MC, Erben P, Schnittger S, Saussele S, Leitner A et al (2010) Molecular response after 3 months of 1st line Imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic myeloid leukemia – a follow-up analysis of the German CML study IV. ASH Annu Meet Abstr 116(21):360

    Google Scholar 

  • Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096–2102, Epub 2012/03/27. eng

    Article  CAS  PubMed  Google Scholar 

  • Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C et al (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 6, Epub 2014/05/07. Eng

    Google Scholar 

  • Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850–858, Epub 1998/06/13. eng

    Article  CAS  PubMed  Google Scholar 

  • Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686–692, Epub 2011/05/04. eng

    Article  CAS  PubMed  Google Scholar 

  • Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370(9584):342–350, Epub 2007/07/31. eng

    Article  CAS  PubMed  Google Scholar 

  • Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12):1634–1642, Epub 2011/03/23. eng

    Article  CAS  PubMed  Google Scholar 

  • Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32(5):415–423, Epub 2013/12/04. eng

    Article  PubMed  Google Scholar 

  • Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28–37, Pubmed Central PMCID: 1895821, Epub 2006/03/09. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758–3765. PubMed PMID: WOS:000284110400015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123(9):1353–1360, Epub 2013/12/18. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M et al (2006a) Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 12(10):3037–3042, Epub 2006/05/19. eng

    Article  CAS  PubMed  Google Scholar 

  • Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D et al (2006b) Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24(3):454–459, Epub 2006/01/20. eng

    Article  CAS  PubMed  Google Scholar 

  • Jabbour E, Kantarjian H, O’Brien S, Shan J, Quintas-Cardama A, Faderl S et al (2011) The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118:4541–4546. Epub 2011/08/02. Eng

    Google Scholar 

  • Jabbour E, Kantarjian H, Ghanem H, O’Brien S, Quintas-Cardama A, Garcia-Manero G et al (2013) The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk 13(3):302–306, Pubmed Central PMCID: 4160838, Epub 2013/01/16. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4):494–500, Epub 2013/12/07. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jain P, Kantarjian H, Nazha A, O’Brien S, Jabbour E, Romo CG et al (2013) Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121(24):4867–4874, Pubmed Central PMCID: 3743466, Epub 2013/04/27. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260–2270, Epub 2010/06/08. eng

    Article  CAS  PubMed  Google Scholar 

  • Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ et al (2012) Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol 96(1):47–57, Epub 2012/05/23. eng

    Article  CAS  PubMed  Google Scholar 

  • Kim DD, Lee H, Kamel-Reid S, Lipton JH (2013) BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Br J Haematol 160(5):630–639, Epub 2013/01/03. eng

    Article  CAS  PubMed  Google Scholar 

  • Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH (2014) BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol 89(6):626–632, Epub 2014/03/13. eng

    Article  CAS  PubMed  Google Scholar 

  • Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A et al (2014) Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 140(11):1965–1969, Epub 2014/06/24. eng

    Article  CAS  PubMed  Google Scholar 

  • Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE (2011) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117(24):6660–6668, Epub 2011/04/15. eng

    Article  CAS  PubMed  Google Scholar 

  • Mahon FX, Faberes C, Pueyo S, Cony-Makhoul P, Salmi R, Boiron JM, Marit G et al (1998) Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood 92:4059–4065. 19990105 DCOM- 19990105(0006-4971 (Print)). eng

    Google Scholar 

  • Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029–1035, Epub 2010/10/23. eng

    Article  CAS  PubMed  Google Scholar 

  • Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112(12):4437–4444, Epub 2008/08/22. eng

    Article  CAS  PubMed  Google Scholar 

  • Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388, Epub 2010/04/14. eng

    Article  CAS  PubMed  Google Scholar 

  • Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R et al (2012a) KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 26(2):296–302, Epub 2011/08/17. eng

    Article  CAS  PubMed  Google Scholar 

  • Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al (2012b) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232–238, Epub 2011/11/10. eng

    Article  CAS  PubMed  Google Scholar 

  • Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D et al (2012c) Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120(2):291–294, Epub 2012/05/31. eng

    Article  CAS  PubMed  Google Scholar 

  • Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al (2002) Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16(9):1579–1583, Epub 2002/08/30. eng

    Article  CAS  PubMed  Google Scholar 

  • Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L et al (2013) Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14):2739–2742, Epub 2013/02/06. eng

    Article  CAS  PubMed  Google Scholar 

  • Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18(4):521–528, Epub 2012/03/20. eng

    Article  CAS  PubMed  Google Scholar 

  • O’Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P et al (2014) Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 12:1590–1610. 20141101(1540-1413 (Electronic)). eng

    Google Scholar 

  • Ohm L, Arvidsson I, Barbany G, Hast R, Stenke L (2012) Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome. Am J Hematol 87(8):760–765, Epub 2012/05/30. eng

    Article  CAS  PubMed  Google Scholar 

  • Perrotti D, Jamieson C, Goldman J, Skorski T (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 120(7):2254–2264, Pubmed Central PMCID: 2898591, Epub 2010/07/02. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12(10):1181–1184, Epub 2006/10/03. eng

    Article  CAS  PubMed  Google Scholar 

  • Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259, Epub 2010/06/08. eng

    Article  CAS  PubMed  Google Scholar 

  • Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brummendorf TH et al (2014) Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 123(15):2317–2324, Epub 2014/02/27. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63(4):789–799, Epub 1984/04/01. eng

    CAS  PubMed  Google Scholar 

  • Stein AM, Martinelli G, Hughes TP, Muller MC, Beppu L, Gottardi E et al (2013) Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer 13:173, Pubmed Central PMCID: 3646679, Epub 2013/04/04. eng

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang L, Pearson K, Ferguson JE, Clark RE (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120(6):990–999, Epub 2003/03/22. eng

    Article  CAS  PubMed  Google Scholar 

  • White DL, Hughes TP (2012) Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. J Clin Oncol 30(10):1144–1145; author reply 5-6. Epub 2012/03/07. eng

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Pettenkoferstrasse 22, Mannheim, 68169, Germany

    Benjamin Hanfstein & Martin C. Müller

  2. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

    Andreas Hochhaus

Authors
  1. Benjamin Hanfstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin C. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Hanfstein .

Editor information

Editors and Affiliations

  1. Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany

    Rüdiger Hehlmann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hanfstein, B., Müller, M.C., Hochhaus, A. (2016). Response-Related Predictors of Survival in CML. In: Hehlmann, R. (eds) Chronic Myeloid Leukemia. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-33198-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33198-0_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33197-3

  • Online ISBN: 978-3-319-33198-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation